Finding the Therapeutic Sweet Spot: Using Naturally Occurring Human Variants to Inform Drug Design.

John R Burnett, Robert A Hegele

Abstract readEditorialComment

In one paragraph

Article in Circulation. Cardiovascular genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it

0cells of the map it votes in

3citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

Genetic determinants of lipid metabolism in cardioprotection: From mechanisms to clinical practice.Biomolecules & biomedicine · 2025
Review
Anticancer potential of aminomethylidene-diazinanes I. Synthesis of arylaminomethylidene of diazinetriones and its cytotoxic effects tested in glioblastoma cells.Bioorganic & medicinal chemistry · 2017
Article
Longevity-Associated FOXO3 Genotype and its Impact on Coronary Artery Disease Mortality in Japanese, Whites, and Blacks: A Prospective Study of Three American Populations.The journals of gerontology. Series A, Biological sciences and medical sciences · 2017
Observational

4 · The record

Corrections and comments

Comment on
Novel Abetalipoproteinemia Missense Mutation Highlights the Importance of the N-Terminal β-Barrel in Microsomal Triglyceride Transfer Protein Function.2015

5 · Who and what money

Authors and funding

2 authors.

John R BurnettFrom the Department of Clinical Biochemistry, PathWest Laboratory Medicine, Royal Perth Hospital, Perth, Western Australia, Australia (J.R.B.); and School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia (J.R.B.); and Department of Medicine and Robarts Research Institute, Schulich School of Medicine, Western University, London, Ontario, Canada (R.A.H.).

Robert A HegeleFrom the Department of Clinical Biochemistry, PathWest Laboratory Medicine, Royal Perth Hospital, Perth, Western Australia, Australia (J.R.B.); and School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia (J.R.B.); and Department of Medicine and Robarts Research Institute, Schulich School of Medicine, Western University, London, Ontario, Canada (R.A.H.). hegele@robarts.ca.

Funding

Canadian Institutes of Health Research MOP-13430Canadian Institutes of Health Research MOP-79523

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AbetalipoproteinemiaAnimalsCarrier ProteinsHumansMaleCarrier Proteinsapolipoproteins Bcholesterol, LDLEditorialsgeneticshumansmutation

Identifiers

PMID26487725

DOI10.1161/CIRCGENETICS.115.001219

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.